AusperBio, a sino-American biotechnology company specializing in liver therapy development, has reportedly secured USD 37 million in a Series A financing round. The round was spearheaded by the InnoPinnacle Fund, with additional investments from a consortium that includes Yuanbio Venture Capital, Hankang Capital, Qiming Venture Partners, and Genesis Capital. The newly raised capital is earmarked for the acceleration of AusperBio’s hepatitis B virus (HBV) therapy AHB-137, focusing on the advancement of Phase II clinical studies, exploration of combination treatments, and Chemistry, Manufacturing, and Controls (CMC) manufacturing processes.
AHB-137 represents an innovative non-conjugated antisense oligonucleotide (ASO) drug candidate that targets all HBV mRNA with specificity. This breakthrough therapy has previously been granted a breakthrough therapy designation (BTD) in China, underscoring its potential to address significant unmet medical needs in the treatment of HBV.- Flcube.com
